Chorea-related mutations in PDE10A result in aberrant compartmentalization and functionality of the enzyme
A robust body of evidence supports the concept that phosphodiesterase 10A (PDE10A) activity in the basal ganglia orchestrates the control of coordinated movement in human subjects. Although human mutations in the PDE10A gene manifest in hyperkinetic movement disorders that phenocopy many features of...
Saved in:
Published in | Proceedings of the National Academy of Sciences - PNAS Vol. 117; no. 1; pp. 677 - 688 |
---|---|
Main Authors | , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
National Academy of Sciences
07.01.2020
|
Subjects | |
Online Access | Get full text |
ISSN | 0027-8424 1091-6490 1091-6490 |
DOI | 10.1073/pnas.1916398117 |
Cover
Summary: | A robust body of evidence supports the concept that phosphodiesterase 10A (PDE10A) activity in the basal ganglia orchestrates the control of coordinated movement in human subjects. Although human mutations in the PDE10A gene manifest in hyperkinetic movement disorders that phenocopy many features of early Huntington’s disease, characterization of the maladapted molecular mechanisms and aberrant signaling processes that underpin these conditions remains scarce. Recessive mutations in the GAF-A domain have been shown to impair PDE10A function due to the loss of striatal PDE10A protein levels, but here we show that this paucity is caused by irregular intracellular trafficking and increased PDE10A degradation in the cytosolic compartment. In contrast to GAF-A mutants, dominant mutations in the GAF-B domain of PDE10A induce PDE10A misfolding, a common pathological phenotype in many neurodegenerative diseases. These data demonstrate that the function of striatal PDE10A is compromised in disorders where disease-associated mutations trigger a reduction in the fidelity of PDE compartmentalization. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Edited by Joseph A. Beavo, University of Washington School of Medicine, Seattle, WA, and approved November 20, 2019 (received for review October 15, 2019) 1Present address: Department of Neurology, University of California, San Francisco, CA, 94158. 2Present address: Jnana Therapeutics, Boston, MA 02210. Author contributions: G.S.T., E.S., N.J.B., and G.S.B. conceived the study; G.S.T., E.L.W., T.Z.D., R.W.B., S.J.M., E.S., N.J.B., and G.S.B. designed research; G.S.T., E.L.W., T.Z.D., and R.W.B. performed experiments and analyzed data; G.S.T., N.J.B., and G.S.B. wrote the paper with input from all authors. |
ISSN: | 0027-8424 1091-6490 1091-6490 |
DOI: | 10.1073/pnas.1916398117 |